Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

Item

http://www.wikidata.org/entity/Q33422543

Q33422543

about

Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.Redefining the BH3 Death Domain as a 'Short Linear Motif'.Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation.miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Targeting indolent non-Hodgkin lymphoma.Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.Promising Novel Agents for Aggressive B-Cell Lymphoma.The landscape of new drugs in lymphoma Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.The BCL-2 arbiters of apoptosis and their growing role as cancer targets.Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs.Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.BCL-2 as therapeutic target for hematological malignancies.

P2860

Q26782270-0E636A80-E842-49CE-A6EC-1B1E18BF0660 Q28075504-5A072019-5595-4B1F-928B-F5E473B33CE6 Q28075683-104D4D5B-47D4-45D2-A973-FEBBD6859C87 Q33438428-95D46779-87D3-4368-A7A2-B4B44CF5C1CD Q33438494-E41160EE-22FA-4001-BA0B-90D7C060DC5D Q37324058-59F7E1A4-E22B-4E69-88FF-7BB5D5706ACD Q37330840-C8D7A473-A05B-458E-9294-C122ACE1B697 Q37521403-40D6E301-6B65-49B6-A486-9E4AEB81EB55 Q37678946-F82678DA-BA09-4FD6-A94F-3E5AEA280AE1 Q38685006-85810D8B-EC38-4456-AFF4-7CF54B0835BB Q38790957-A436872C-5DB2-4274-B9D2-85A114F37776 Q38819164-3D8E1027-55B8-40CA-8320-41425F7CC503 Q38917848-964A6287-6CC0-48EE-8C11-A6FE55AB74D3 Q38996888-3B1200B4-7DE7-4F3C-9D24-468DAB4244A6 Q39013616-D18F3462-1D4D-4A85-A31A-56F1A2F4E9BC Q39020641-C33F7EE2-3A87-405D-9593-5E4C74333DAA Q39061630-BB0CAC42-7770-4D3D-B2DF-57C5E1988032 Q39267135-CFD29444-DF70-4926-96C0-0234E5FFF5A2 Q42503679-9EFE0101-993A-4187-9517-4B9A15ED6ACC Q46370948-6AC86DA0-2531-497F-852F-2BB91DACD068 Q47166330-12E31A40-12A9-43D5-9A06-9796801605A0 Q47324655-359F529A-996E-43B1-8059-85E27953F801 Q47932240-0D9C6271-CFD0-4BEC-9C5F-EC0BB06EEFF6 Q53684488-1DB8BE75-CEB2-4EB9-BA01-3264B726C219

P2860

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

Item

http://www.wikidata.org/entity/Q33422543

description

2015 nî lūn-bûn

@nan

2015 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu